JP2002525099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002525099A5 JP2002525099A5 JP2000572253A JP2000572253A JP2002525099A5 JP 2002525099 A5 JP2002525099 A5 JP 2002525099A5 JP 2000572253 A JP2000572253 A JP 2000572253A JP 2000572253 A JP2000572253 A JP 2000572253A JP 2002525099 A5 JP2002525099 A5 JP 2002525099A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- variant
- native
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 230000002163 immunogen Effects 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 239000003623 enhancer Substances 0.000 claims 6
- 238000003780 insertion Methods 0.000 claims 6
- 230000037431 insertion Effects 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 238000007792 addition Methods 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 230000015788 innate immune response Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108010081208 RMFPNAPYL Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010073443 Ribi adjuvant Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/164,223 | 1998-09-30 | ||
| US09/164,223 US7063854B1 (en) | 1998-09-30 | 1998-09-30 | Composition and methods for WTI specific immunotherapy |
| US27648499A | 1999-03-25 | 1999-03-25 | |
| US09/276,484 | 1999-03-25 | ||
| PCT/US1999/022819 WO2000018795A2 (en) | 1998-09-30 | 1999-09-30 | Compositions and methods for wt1 specific immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006227215A Division JP2007001984A (ja) | 1998-09-30 | 2006-08-23 | Ｗｔ１特異的免疫療法のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002525099A JP2002525099A (ja) | 2002-08-13 |
| JP2002525099A5 true JP2002525099A5 (enExample) | 2005-06-09 |
| JP4243792B2 JP4243792B2 (ja) | 2009-03-25 |
Family
ID=26860363
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000572253A Expired - Fee Related JP4243792B2 (ja) | 1998-09-30 | 1999-09-30 | Ｗｔ１特異的免疫療法のための組成物および方法 |
| JP2006227215A Pending JP2007001984A (ja) | 1998-09-30 | 2006-08-23 | Ｗｔ１特異的免疫療法のための組成物および方法 |
| JP2007279673A Expired - Fee Related JP4235984B2 (ja) | 1998-09-30 | 2007-10-26 | Ｗｔ１特異的免疫療法のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006227215A Pending JP2007001984A (ja) | 1998-09-30 | 2006-08-23 | Ｗｔ１特異的免疫療法のための組成物および方法 |
| JP2007279673A Expired - Fee Related JP4235984B2 (ja) | 1998-09-30 | 2007-10-26 | Ｗｔ１特異的免疫療法のための組成物および方法 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1117687B1 (enExample) |
| JP (3) | JP4243792B2 (enExample) |
| KR (1) | KR100752065B1 (enExample) |
| CN (1) | CN100486995C (enExample) |
| AR (1) | AR021849A1 (enExample) |
| AT (1) | ATE399179T1 (enExample) |
| AU (1) | AU6407899A (enExample) |
| BR (1) | BR9914116A (enExample) |
| CA (1) | CA2349442C (enExample) |
| CZ (1) | CZ20011144A3 (enExample) |
| DE (1) | DE69938970D1 (enExample) |
| ES (1) | ES2310052T3 (enExample) |
| HK (1) | HK1039782B (enExample) |
| HU (1) | HUP0103598A3 (enExample) |
| IL (2) | IL142216A0 (enExample) |
| MX (1) | MXPA01003344A (enExample) |
| MY (1) | MY139226A (enExample) |
| NO (1) | NO325839B1 (enExample) |
| NZ (1) | NZ510600A (enExample) |
| PL (1) | PL201881B1 (enExample) |
| RU (1) | RU2237674C2 (enExample) |
| SA (1) | SA00200872B1 (enExample) |
| TR (1) | TR200101482T2 (enExample) |
| TW (1) | TWI285648B (enExample) |
| WO (1) | WO2000018795A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| PT1103564E (pt) * | 1998-07-31 | 2009-03-13 | Int Inst Cancer Immunology Inc | Antigénios de cancro com base no produto do gene supressor de tumor wt1 |
| US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
| US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030072767A1 (en) * | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| AU7859900A (en) * | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| CA2401070A1 (en) * | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| JP4592641B2 (ja) * | 2000-05-24 | 2010-12-01 | 治夫 杉山 | Ｗｔ１関連疾患の検査方法 |
| JP3846199B2 (ja) | 2000-05-24 | 2006-11-15 | 治夫 杉山 | Ｗｔ１関連疾患の検査方法 |
| US20040097703A1 (en) * | 2001-03-22 | 2004-05-20 | Haruo Sugiyama | Wt1 modified peptide |
| ATE494905T1 (de) * | 2001-06-29 | 2011-01-15 | Chugai Pharmaceutical Co Ltd | Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom |
| US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| JPWO2003028758A1 (ja) * | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的ｔ細胞の誘導方法 |
| WO2003028757A1 (en) * | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| JP4365784B2 (ja) * | 2002-06-12 | 2009-11-18 | 株式会社癌免疫研究所 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| WO2004024175A1 (ja) * | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| EP1548028B1 (en) * | 2002-09-20 | 2009-09-09 | International Institute of Cancer Immunology, Inc. | Substituted type peptides of wt1 |
| ES2332590T3 (es) * | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
| KR101431312B1 (ko) | 2003-06-27 | 2014-08-20 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ1 백신 적응 환자의 선택 방법 |
| PL2071028T3 (pl) * | 2003-11-05 | 2012-06-29 | Int Inst Cancer Immunology Inc | Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR |
| EP2186896B1 (en) | 2004-03-31 | 2015-11-04 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptides derived from WT1 |
| EP1657250A1 (en) * | 2004-11-11 | 2006-05-17 | Charité - Universitätsmedizin Berlin | HLA-A *01-binding T-cell epitope of WT1 |
| RU2286146C1 (ru) * | 2005-04-12 | 2006-10-27 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения церебральных метастазов генерализованной меланомы кожи |
| RU2301061C2 (ru) * | 2005-04-28 | 2007-06-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения генерализованной меланомы кожи |
| RU2424247C2 (ru) | 2005-11-30 | 2011-07-20 | Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. | Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка |
| DK2518149T3 (en) * | 2006-02-22 | 2016-01-11 | Int Inst Cancer Immunology Inc | HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| ES2545457T3 (es) * | 2006-10-17 | 2015-09-11 | Oncotherapy Science, Inc. | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 |
| CN101573448B (zh) * | 2006-12-28 | 2012-07-11 | 株式会社癌免疫研究所 | Hla-a*1101限制的wt1肽及含有其的药物组合物 |
| ES2559062T3 (es) | 2007-02-27 | 2016-02-10 | International Institute Of Cancer Immunology, Inc. | Método para la activación de linfocitos T colaboradores y composición para su uso en el método |
| DK2918598T3 (en) * | 2007-02-28 | 2019-04-29 | The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services | Brachyury polypeptides and methods of use |
| KR101669279B1 (ko) | 2007-03-05 | 2016-10-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| EP2216041A4 (en) * | 2007-11-20 | 2012-10-24 | Nec Corp | METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR |
| KR101610664B1 (ko) * | 2007-12-05 | 2016-04-08 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 백신 조성물 |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| WO2010135394A1 (en) * | 2009-05-19 | 2010-11-25 | University Of Miami | Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
| AR083295A1 (es) | 2010-10-05 | 2013-02-13 | Univ Osaka | Metodo para activar celulas t auxiliares |
| JP6082997B2 (ja) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| CN103764826A (zh) | 2011-06-28 | 2014-04-30 | 株式会社癌免疫研究所 | 肽癌抗原-特异性t细胞的受体基因 |
| ES2655031T3 (es) | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
| KR102158225B1 (ko) | 2012-12-17 | 2020-09-21 | 오츠카 세이야쿠 가부시키가이샤 | 헬퍼 t세포의 활성화 방법 |
| JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
| US10588952B2 (en) | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
| WO2014157692A1 (ja) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| CN111781359A (zh) * | 2013-05-13 | 2020-10-16 | 株式会社癌免疫研究所 | 用于预测免疫疗法的临床效果的方法 |
| CN106170297A (zh) * | 2013-09-20 | 2016-11-30 | 纪念斯隆-凯特琳癌症中心 | 用于wt‑1‑阳性疾病的组合/辅助疗法 |
| EP3112378B1 (en) | 2014-02-26 | 2020-06-24 | Tella, Inc. | Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide |
| KR102797324B1 (ko) * | 2014-12-11 | 2025-04-22 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 혈관 신생병의 면역 요법 |
| JP6947720B2 (ja) * | 2015-09-10 | 2021-10-13 | メモリアル スローン ケタリング キャンサー センター | Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法 |
| CN116327902A (zh) * | 2015-11-20 | 2023-06-27 | 纪念斯隆凯特林癌症中心 | 用于治疗癌症的方法和组合物 |
| CN105254760B (zh) * | 2015-11-21 | 2018-08-17 | 福州迈新生物技术开发有限公司 | 一株分泌抗wt1蛋白的单克隆抗体及其应用 |
| EP3549957A4 (en) | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER |
| US20210100886A1 (en) | 2017-03-30 | 2021-04-08 | Sumitomo Dainippon Pharma Co., Ltd. | Wt1 cancer antigen peptides and peptide conjugates comprising the peptides |
| CN111533796A (zh) * | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| CN111527107B (zh) | 2017-12-21 | 2024-10-01 | 豪夫迈·罗氏有限公司 | 结合hla-a2/wt1的抗体 |
| CN109758575B (zh) * | 2018-02-14 | 2022-08-30 | 上海微球生物科技有限公司 | 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用 |
| WO2020067453A1 (ja) | 2018-09-28 | 2020-04-02 | 大日本住友製薬株式会社 | 注射用組成物 |
| TW202528332A (zh) | 2019-02-28 | 2025-07-16 | 日商住友製藥股份有限公司 | 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法 |
| TW202200188A (zh) | 2020-05-12 | 2022-01-01 | 日商大日本住友製藥股份有限公司 | 用以處置癌症之醫藥組合物 |
| EP4149534A4 (en) * | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
| KR20220034563A (ko) * | 2020-09-11 | 2022-03-18 | 한국생명공학연구원 | 신규 치주 질환 특이 항체 및 이의 용도 |
| KR102476515B1 (ko) * | 2020-09-11 | 2022-12-12 | 한국생명공학연구원 | 치주 질환 특이 항체 및 이의 용도 |
| CN118076382A (zh) | 2021-08-12 | 2024-05-24 | 株式会社癌免疫研究所 | 用于治疗或预防癌症的药用组合物和方法 |
| EP4410304A4 (en) * | 2021-09-24 | 2025-08-27 | Cha Vaccine Res Institute Co Ltd | CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM A TUMOR-ASSOCIATED ANTIGEN, AND AN ADJUVANT CONSISTING OF A LIPOPEPTIDE AND AN IMMUNOACTIVE SUBSTANCE, AND USE THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0453560B1 (en) * | 1989-11-13 | 1999-05-26 | Massachusetts Institute Of Technology | Localization and characterization of the wilms' tumor gene |
| RU2100369C1 (ru) * | 1992-04-22 | 1997-12-27 | Варнер-Ламберт Компани | Производные пептида или их фармацевтически приемлемые соли |
| US5705159A (en) * | 1993-08-31 | 1998-01-06 | John Wayne Cancer Institute | Immunoreactive peptide sequence from a 43 KD human cancer antigen |
| US5622835A (en) * | 1994-04-28 | 1997-04-22 | The Wistar Institute Of Anatomy & Biology | WT1 monoclonal antibodies |
| AU3896899A (en) * | 1998-05-11 | 1999-11-29 | Salk Institute For Biological Studies, The | Compositions for the treatment of tumors, and uses thereof |
| PT1103564E (pt) * | 1998-07-31 | 2009-03-13 | Int Inst Cancer Immunology Inc | Antigénios de cancro com base no produto do gene supressor de tumor wt1 |
-
1999
- 1999-09-30 BR BR9914116-7A patent/BR9914116A/pt not_active Application Discontinuation
- 1999-09-30 AR ARP990104969A patent/AR021849A1/es active IP Right Grant
- 1999-09-30 CN CNB998133493A patent/CN100486995C/zh not_active Expired - Fee Related
- 1999-09-30 ES ES99951690T patent/ES2310052T3/es not_active Expired - Lifetime
- 1999-09-30 CA CA2349442A patent/CA2349442C/en not_active Expired - Fee Related
- 1999-09-30 MY MYPI99004243A patent/MY139226A/en unknown
- 1999-09-30 AT AT99951690T patent/ATE399179T1/de not_active IP Right Cessation
- 1999-09-30 PL PL348595A patent/PL201881B1/pl not_active IP Right Cessation
- 1999-09-30 JP JP2000572253A patent/JP4243792B2/ja not_active Expired - Fee Related
- 1999-09-30 TR TR2001/01482T patent/TR200101482T2/xx unknown
- 1999-09-30 MX MXPA01003344A patent/MXPA01003344A/es not_active IP Right Cessation
- 1999-09-30 AU AU64078/99A patent/AU6407899A/en not_active Abandoned
- 1999-09-30 EP EP99951690A patent/EP1117687B1/en not_active Expired - Lifetime
- 1999-09-30 CZ CZ20011144A patent/CZ20011144A3/cs unknown
- 1999-09-30 RU RU2001111834A patent/RU2237674C2/ru not_active IP Right Cessation
- 1999-09-30 IL IL14221699A patent/IL142216A0/xx unknown
- 1999-09-30 DE DE69938970T patent/DE69938970D1/de not_active Expired - Lifetime
- 1999-09-30 HU HU0103598A patent/HUP0103598A3/hu unknown
- 1999-09-30 HK HK02100544.9A patent/HK1039782B/en unknown
- 1999-09-30 KR KR1020017004049A patent/KR100752065B1/ko not_active Expired - Fee Related
- 1999-09-30 WO PCT/US1999/022819 patent/WO2000018795A2/en not_active Ceased
- 1999-09-30 NZ NZ510600A patent/NZ510600A/en not_active IP Right Cessation
- 1999-12-22 TW TW094123744A patent/TWI285648B/zh active
-
2000
- 2000-01-22 SA SA00200872A patent/SA00200872B1/ar unknown
-
2001
- 2001-03-22 IL IL142216A patent/IL142216A/en not_active IP Right Cessation
- 2001-03-29 NO NO20011613A patent/NO325839B1/no not_active IP Right Cessation
-
2006
- 2006-08-23 JP JP2006227215A patent/JP2007001984A/ja active Pending
-
2007
- 2007-10-26 JP JP2007279673A patent/JP4235984B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002525099A5 (enExample) | ||
| CA2465303A1 (en) | Compositions and methods for wt1 specific immunotherapy | |
| JP2010500399A5 (enExample) | ||
| US6126945A (en) | Tumor killing effects of enterotoxins, superantigens, and related compounds | |
| EP0427347B1 (en) | Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines | |
| JP2008530245A5 (enExample) | ||
| JP4130359B2 (ja) | Ｗｔ１特異的免疫療法のための組成物および方法 | |
| CA1148146A (en) | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture | |
| CA2349442A1 (en) | Compositions and methods for wt1 specific immunotherapy | |
| JP2004535187A (ja) | アジュバントとしてのコレラホロトキシンの突然変異形 | |
| RU2011121043A (ru) | ВАКЦИНА ПРОТИВ ПЕПТИДА CH3 IgE | |
| WO1993024136A1 (en) | Tumor killing effects of enterotoxins, superantigens, and related compounds | |
| RU2006105498A (ru) | Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus | |
| ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
| JP2003533181A (ja) | ムチン−１誘導抗原および免疫療法におけるその使用 | |
| BR9812240A (pt) | Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica | |
| ES2702325T3 (es) | Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas | |
| JP2003535906A (ja) | アジュバントの組み合わせとしてのｑｓ−２１及びｉｌ−１２ | |
| FI924222A0 (fi) | Gp75 som ett tumoervaccin mot melanoma. | |
| JP2001515723A (ja) | Ａ群連鎖球菌ワクチン | |
| JP2005512518A5 (enExample) | ||
| JPH05506234A (ja) | ワクチン組成物 | |
| JP2020536925A5 (enExample) | ||
| JP2018511659A5 (enExample) | ||
| EP0785947B1 (en) | Peptides endowed with antiinflammatory activity |